gms | German Medical Science

21. Jahrestagung der Deutschen Gesellschaft für Pädiatrische Infektiologie (DGPI)

Deutsche Gesellschaft für Pädiatrische Infektiologie (DGPI)

25.04. - 27.04.2013, Würzburg

Anti-Interleukin-6 (IL-6) and Anti-TNF-alpha treatments do not have a negative impact on the Cytomegalovirus- (CMV) specific Interferon-gamma immune response in children with Juvenile Idiopathic Arthritis (JIA) in vitro

Meeting Abstract

  • corresponding author presenting/speaker R. Trippen - University of Wuerzburg, Department of Pediatrics - Wuerzburg, Deutschland
  • G. Almanzar - University of Wuerzburg, Department of Pediatrics - Wuerzburg, Deutschland
  • K. Sustal - University of Wuerzburg, Department of Pediatrics - Wuerzburg, Deutschland
  • K. Höfner - University of Wuerzburg, Department of Pediatrics - Wuerzburg, Deutschland
  • M. Prelog - University of Wuerzburg, Department of Pediatrics - Wuerzburg, Deutschland

Deutsche Gesellschaft für Pädiatrische Infektiologie. 21. Jahrestagung der Deutschen Gesellschaft für Pädiatrische Infektiologie (DGPI). Würzburg, 25.-27.04.2013. Düsseldorf: German Medical Science GMS Publishing House; 2013. Doc13dgpi50

doi: 10.3205/13dgpi50, urn:nbn:de:0183-13dgpi501

Published: March 28, 2013

© 2013 Trippen et al.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by-nc-nd/3.0/deed.en). You are free: to Share – to copy, distribute and transmit the work, provided the original author and source are credited.


Outline

Text

Background: Previous studies showed lower proportions of CD28+ T-cells in Cytomegalovirus (CMV)-seropositive healthy donors (HD), which could not be shown in patients with Juvenile Idiopathic Arthritis (JIA), a T-cell-mediated autoimmune disease in children and adolescents. However, data on CMV-specific immune responses in JIA patients on anti-cytokine-treatments are missing.

Objective: This study determined the CMV-specific immune response in patients with JIA and age-matched HD using in vitro blockade of Interleukin-6(IL-6) and tumour-necrosis-factor-alpha(TNFalpha).

Methods: Peripheral blood mononuclear cells (PBMCs) and serum samples were obtained from 5 JIA patients in clinical remission on medication with non-steroidal anti-rheumatic drugs and 4 HD. CMV-specific IFNgamma-production was determined by ELISPOT following stimulation with CMV-antigens (CMVpp65,CMV-IE) in combination with monoclonal antibodies against IL-6 and TNFalpha. Results were expressed in spot forming units (SFU)/1000000 cells.

Results: CMV-seropositive JIA patients showed a significant higher number of IFNgamma-producing effector T-cells (CD4+CD45RA-CD28-) (39.03%) than CMV-seronegative JIA patients (16.55%). No differences were found in the IFNgamma-production between HD and JIA in the presence of anti-TNFalpha (JIA:27.8% vs. HD:27.3%), but a trend to lower IFNgamma-production by anti-IL-6 (JIA:13.3% vs. HD:35.0%). Within the JIA group, the IFNgammma-production following CMVpp65 stimulation was slightly lower in the presence of anti-IL-6 (CMVpp65:25.6% vs. CMVpp65+anti-IL-6:13.3.%) but not affected by anti-TNFalpha (CMVpp65:25.56% vs. CMVpp65+anti-TNFalpha:27. 8%).

Conclusion: Our preliminary findings did not reveal a significantly altered immune response in JIA patients against CMV in vitro. However, long-term aspects of chronic stimulation of the T-cell immune system by CMV as known from healthy elderly persons resulting in exhaustion of CD28- T-cells may follow in older age.